Woburn-based Frequency Therapeutics has entered into an exclusive license agreement with Tokyo’s Astellas Pharma to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss. At present, there are no approved therapeutic options for sensorineural hearing loss. Frequency will receive an upfront payment […]

Bristol-Myers Squibb recently provided an update on the approval process and timeline for its pending merger with Celgene. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, BMS is planning the divestiture of its anti-inflammatory drug Otezla (apremilast). The divestiture is subject to further review by […]

Karyopharm Therapeutics has announced that the FDA has approved its drug Xpovio (selinexor) in combination with dexamethasone for the treatment of certain adult patients with relapsed or refractory multiple myeloma (RRMM). Approval was granted under the Accelerated Approval Program which was developed by the FDA to allow for expedited approval of drugs that treat serious […]

AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock on June 24, 2019. “This is a transformational transaction for both […]

What are the strategic and financial benefits of this transaction? This transaction achieves unique and complementary strategic objectives for both organizations. Combining Allergan’s diversified on-market product portfolio with AbbVie’s growth platform and deep expertise in R&D, commercial strength and international footprint will create a leading biopharmaceutical company with approximately$48 billion in combined 2019 revenue. This […]